NON-MYELOBLATIVE HAPLOIDENTICAL HSCT WITH NK CELL INFUSIONS IN HIGH RISK MYELOID

高风险骨髓中 NK 细胞输注的非成髓性单倍体 HSCT

• 批准号: 7375910
• 负责人: DANIEL J WEISDORF
• 金额: $ 0.48万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375910
• 关键词: NON; MYELOBLATIVE; HAPLOIDENTICAL; HSCT; NK

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the effects of an infusion of natural killer (NK) celss given to patients receiving a reduced intensity pre-transplant regimen and stem cell trnsplant from a haploidentical related donor. Our hypothesis is that the addition of NK cells to this standard regimen will reduce the incidence of GVHD without compromising engraftment or leading to excess day +100 mortality. Additionally, the NK cell infusion may limit the risks of cancer relapse after transplant. We are also testing the safety of the NK cell infusion.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究旨在评估接受低强度移植前方案和单倍体相关供体干细胞移植的患者输注自然杀伤细胞（NK）的效果。我们的假设是，在标准方案中加入NK细胞将降低GVHD的发病率，而不会影响移植或导致额外的day +100死亡率。此外，NK细胞输注可能限制移植后癌症复发的风险。我们也在测试NK细胞输注的安全性。